Literature DB >> 19830602

Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature.

Halit Karaca1, Ayhan Lale, Mustafa Dikilitas, Metin Ozkan, Ozlem Er.   

Abstract

Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor. It has higher response rates and progression-free survival in patients with metastatic renal cell carcinoma (RCC) when compared with standard chemotherapy and interferon-alpha. We report a case of paraneoplastic hypercalcemia, resistant to conventional treatment but recovers by sunitinib treatment as the first case in the literature, in a 33-years-old man with metastatic RCC. At the sixth month of follow-up period, in this case, serum calcium level was still in normal ranges. Besides sunitinib is effective in symptom control, it is also helpful in management of paraneoplastic hypercalcemia, a life-threatening entity.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19830602     DOI： 10.1007/s12032-009-9327-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  25 in total

Review 1.  The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing.

Authors:  William G Kaelin
Journal:  Biochem Biophys Res Commun       Date:  2005-08-30       Impact factor: 3.575

2.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  Rapidly relapsing squamous cell carcinoma of the renal pelvis associated with paraneoplastic syndromes of leukocytosis, thrombocytosis and hypercalcemia.

Authors:  O Er; H S Coşkun; M Altinbaş; H Akgün; M Cetin; B Eser; A Unal
Journal:  Urol Int       Date:  2001       Impact factor: 2.089

5.  Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.

Authors:  B Escudier; C Chevreau; C Lasset; J Y Douillard; A Ravaud; M Fabbro; A Caty; J F Rossi; P Viens; J P Bergerat; J Savary; S Négrier
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

6.  Hypercalcemia in the emergency department.

Authors:  Chien-Te Lee; Chih-Chao Yang; King-Kwan Lam; Chia-Te Kung; Chia-Jung Tsai; Hung-Chun Chen
Journal:  Am J Med Sci       Date:  2006-03       Impact factor: 2.378

7.  SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Authors:  Tinya J Abrams; Leslie B Lee; Lesley J Murray; Nancy K Pryer; Julie M Cherrington
Journal:  Mol Cancer Ther       Date:  2003-05       Impact factor: 6.261

8.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Jennifer Bacik; Lawrence H Schwartz; Victor Reuter; Paul Russo; Stephanie Marion; Madhu Mazumdar
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

9.  SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.

Authors:  Lesley J Murray; Tinya J Abrams; Kelly R Long; Theresa J Ngai; Lisa M Olson; Weiru Hong; Paul K Keast; Jacqueline A Brassard; Anne Marie O'Farrell; Julie M Cherrington; Nancy K Pryer
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 10.  Renal cell carcinoma presenting with paraneoplastic hypercalcemic coma: a case report and review of the literature.

Authors:  Kara Pepper; Uraporn Jaowattana; Michael D Starsiak; Raghuueer Halkar; Kelly Hornaman; Wenli Wang; Priya Dayamani; Vin Tangpricha
Journal:  J Gen Intern Med       Date:  2007-04-19       Impact factor: 5.128
View more
  3 in total

Review 1.  Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?

Authors:  Daniel Keizman; Maya Ish-Shalom; Natalie Maimon; Maya Gottfried
Journal:  World J Urol       Date:  2013-03-31       Impact factor: 4.226

2.  Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.

Authors:  Jason Adhikaree; Yvette Newby; Santhanam Sundar
Journal:  BMJ Case Rep       Date:  2014-01-30

Review 3.  Skeletal metastasis in renal cell carcinoma: A review.

Authors:  Masood Umer; Yasir Mohib; Muhammed Atif; Muhammad Nazim
Journal:  Ann Med Surg (Lond)       Date:  2018-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.